Clinical development to PoC of a novel oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME)

新型口服血浆激肽释放酶抑制剂用于治疗糖尿病性黄斑水肿 (DME) 的 PoC 临床开发

• 批准号: 102334
• 金额: $ 288.86万
• 依托单位: KALVISTA PHARMACEUTICALS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102334
• 关键词: Clinical; development; PoC; novel; oral

Retinopathy (damage to blood vessels in the retina at the back of the eye) is a serious and common complication of diabetes that can lead to blindness. One of the main problems is that the blood vessels become leaky which allows fluid to escape and accumulate in the retina. There are a limited number of treatment options; laser therapy is commonly used, or alternatively injections into the eye of drugs known to prevent leakiness, although this doesn’t work for every patient. Recently KalVista scientists showed that large amounts of a protein called plasma kallikrein causes the blood vessel leakiness and that a drug which can block plasma kallikrein effectively could become a breakthrough treatment for retinopathy. KalVista is a pharmaceutical company that has extensively studied plasma kallikrein and is proposing to use this experience to develop an oral drug that will block the action of plasma kallikrein which could lead to a brand new treatment for this debilitating and devastating disease.

视网膜病变（眼睛后部视网膜血管受损）是糖尿病的一种严重且常见的并发症，可导致失明。其中一个主要问题是血管变得渗漏，这使得液体逸出并积聚在视网膜中。治疗方法有限;激光治疗是常用的，或者是注射到眼睛里的药物，以防止渗漏，尽管这并不适用于每个病人。最近，KalVista的科学家们发现，大量的一种叫做血浆激肽释放酶的蛋白质会导致血管渗漏，一种可以有效阻断血浆激肽释放酶的药物可能成为视网膜病变的突破性治疗方法。KalVista是一家广泛研究血浆激肽释放酶的制药公司，并计划利用这一经验开发一种口服药物，该药物将阻断血浆激肽释放酶的作用，这可能导致这种使人衰弱和毁灭性疾病的全新治疗方法。